Copeptin: Up-to-date diagnostic and prognostic role highlight

Abdelmageed, M K; Güzelgül, Figen

doi:10.1016/j.ab.2023.115181

Cited by 8 publications

(2 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TR-FRET immunoassay method combines the FRET technology of the reagent with the time-resolved measuring technology of the instrument [ 28 , 29 ]. As an example, using the sandwich method, the schematic diagram of fluorescence resonance energy transfer is shown in Figure 1 .…”

Section: Principle Of Tr-fret Immunoassaymentioning

confidence: 99%

Immunoassay System Based on the Technology of Time-Resolved Fluorescence Resonance Energy Transfer

Xu,

Zhou,

et al. 2024

Sensors

View full text Add to dashboard Cite

To enhance the specificity and sensitivity, cut the cost, and realize joint detection of multiple indicators, an immunoassay system based on the technology of time-resolved fluorescence resonance energy transfer (TR-FRET) was studied. Due to the FRET of the reagent, the donor probe and acceptor probe emitted specific fluorescence to enhance specificity. Long-lifetime specific fluorescence from the acceptor probe was combined with time-resolved technology to enhance sensitivity. A xenon flash lamp and a photomultiplier tube (PMT) were selected as the light source and detector, respectively. A filter-switching mechanism was placed in the light path, so the fluorescence signal from the donor and acceptor was measured alternately. The instrument’s design is given, and some specificI parts are described in detail. Key technical specifications of the instrument and procalcitonin (PCT), C-reactive protein (CRP), and interleukin-6(IL-6) were tested, and the test results were presented subsequently. The CV value of the self-designed counting module is better than 0.01%, and the instrument noises for 620 nm and 665 nm are 41.44 and 10.59, respectively. When set at 37 °C, the temperature bias (B) is 0.06 °C, and the temperature fluctuation is 0.10 °C. The CV and bias are between ±3% and 5%, respectively, when pipetting volumes are between 10 μL and 100 μL. Within the concentration range of 0.01 nM to 10 nM, the luminescence values exhibit linear regression correlation coefficients greater than 0.999. For PCT detection, when the concentration ranges from 0.02 ng/mL to 50 ng/mL, the correlation coefficient of linear fitting exceeds 0.999, and the limit of quantification is 0.096 ng/mL. For CRP and IL-6, the detection concentration ranges from 0 ng/mL to 500 ng/mL and 0 ng/mL to 20 ng/mL, respectively, with limits of quantification of 2.70 ng/mL and 2.82 ng/mL, respectively. The experimental results confirm the feasibility of the technical and instrumental solutions.

show abstract

Section: Principle Of Tr-fret Immunoassaymentioning

confidence: 99%

Immunoassay System Based on the Technology of Time-Resolved Fluorescence Resonance Energy Transfer

Xu,

Zhou,

et al. 2024

Sensors

View full text Add to dashboard Cite

show abstract

“…Fifth, copeptin is a biomarker quantifying endogenous stress, which can be elevated in several other conditions apart from AMI, such as diabetes, renal disease, heart failure, and even psychological stress. 10 Therefore, using copeptin in addition to troponin could lead to higher false-positive rates for detecting AMI. At the same time, it might help to recognize alternative diagnoses as mentioned above, requiring further evaluation.…”

mentioning

confidence: 99%

Ready for rapid rule-out of acute myocardial infarction

Aarts,

Camaro,

van Royen

2023

European Heart Journal

View full text Add to dashboard Cite

Graphical Abstract Graphical Abstract Pros and cons of a dual biomarker strategy for patients with a suspected acute myocardial infarction (AMI). Suspected AMI patients are transported to the emergency department (ED) to rule-in or rule-out an AMI. Chest pain is the most common reason for emergency medical contact and ED overcrowding is a growing problem worldwide. To reduce ED overcrowding, the efficiency of the diagnostic pathway of chest pain needs to improve. The AROMI study proposes an accelerated dual biomarker strategy to reduce the length of stay in the ED, which could reduce ED overcrowding. Pre-hospital strategies for rule-out of AMI could also improve the efficiency of the diagnostic pathway of chest pain. Together with pre-hospital strategies, the AROMI study further opens the door to rapid rule-out of AMI.

show abstract